The Runway Illusion: Why Clinical-Stage Biotech CFOs Are Systematically Under-Modeling Their Path to Readout

1. What the Timeline Data Actually Say

The Phase 2 duration benchmark most CFOs use in board decks is 18 to 24 months. The published figure is 35 months. That discrepancy is not a rounding error — it is 11 months of unbudgeted burn at whatever your clinical-stage run rate happens to be.

Wong, Siah & Lo (2019) analyzed 21,143 compounds across 406,038 trial entries on ClinicalTrials.gov. Mean Phase 1 duration: 1.6 years. Mean Phase 2 duration: 2.9 years. Mean Phase 3: 3.8 years. Citeline-derived data show median Phase 2 length rising from 33 months in 2006 to 39 months post-2015. Neither figure is 18 months.

The delay data compound the problem. Tufts CSDD found that only 47% of trials completed enrollment on the planned timeline — meaning 53% extended. JAMA Surgery's 2023 cross-sectional study of 2,542 RCTs found the median delay was 12.2 months, that fewer than one in five trials finished within their planned timeframe, and that the median enrollment shortfall was 31% of the planned sample size. Separately, Tufts CSDD has reported that roughly 85% of trials experience enrollment-related delays and approximately 30% of investigator sites enroll zero patients.

None of this is obscure. All of it is in the public literature. The reason it does not show up in CFO models is that the 18-month figure is inherited — from SaaS-era VC runway convention, not from drug development timelines.

2. What Trials Actually Cost

Sertkaya, Wong, Jessup & Beleche (Clinical Trials, 2016 — Medidata, US sites, 2004–2012, 2013 USD) is the most granular public dataset on per-trial cost by therapeutic area. Inflated to 2025 USD at roughly 30% CPI uplift:

Phase 2 oncology: $14.5M per study. Phase 2 immunomodulation: $20.8M. Phase 2 hematology: $25.5M. Phase 3 pain and anesthesia: $69M. Phase 1 immunomodulation: $8.6M. These are direct trial costs — not total program costs.

Add corporate G&A and CMC overhead, which at clinical-stage companies typically runs 1.5 to 2× direct trial cost. Add the protocol amendment load: Tufts CSDD's 2023–2024 cohort found 76% of protocols had at least one substantial amendment, at a median direct cost of $141K per Phase 2 amendment. Programs average 2.2 amendments. That is an additional $310K in direct amendment cost — before accounting for the schedule impact, which Getz et al. (2016) put at roughly three months of added trial duration per amendment.

The honest Phase 2 oncology program budget, from IND filing to primary completion readout, is $28M to $40M in 2025 dollars, depending on indication and complexity. At a typical Phase 2 burn rate of $3M to $5M per month — consistent with published 10-K data across IO Biotech, Cabaletta Bio, Bolt Biotherapeutics, and others reviewed here — that envelope requires 24 to 30 months of funded runway minimum. Not 18.

DiMasi, Grabowski & Hansen (Journal of Health Economics, 2016) put out-of-pocket Phase 2 cost per program at $58.6M in 2013 dollars — approximately $76M in 2025 dollars — on a risk-adjusted, capitalized basis. Mulcahy et al. (JAMA Network Open, January 2025 — 268 firms, 1,311 firm-years from SEC 10-K filings) estimated total mean R&D cost per approved drug at $1.31B with a standard deviation of $1.92B. The standard deviation exceeds the mean. Point-estimate budgeting in that distribution is structurally wrong.

3. Worked Scenario — The $75M Biotech

Setup. Private clinical-stage biotech. Single Phase 2 oncology program. $75M cash at IND filing. Monthly burn currently $2.8M (20 FTEs, preclinical wind-down tail). Post-FPI burn expected to rise to $4.2M per month as sites activate, CRO ramp begins, and CMC supply runs.

Base case (protocol on time, no amendments):

Months 0–4 (IND activation → FPI, site contracting, IRB): $2.8M × 4 = $11.2M

Months 4–31 (Phase 2 enrollment + follow-up, 27 months at Wong/Siah/Lo mean): $4.2M × 27 = $113.4M

Months 31–34 (data lock, CSR, readout): $3.5M × 3 = $10.5M

Total consumed: $135.1M

Cash at readout: $75M − $135.1M = −$60.1M → requires a bridge or Series B at month ~18

Slip case (+12.2 months median delay per JAMA Surgery + one protocol amendment):

Add 12.2 months at $4.2M = $51.2M

Protocol amendment direct cost + 3-month schedule impact: $0.14M + $4.2M × 3 = $12.7M

Total: $199M consumed → financing gap of $124M

Implication of the scenario. The "$75M at IND" narrative of being funded to readout is false at industry-norm timelines for a Phase 2 oncology program. The honest number is $100M to $135M on base case, rising to $175M or more on the slip case. The required bridge or Series B arrives at month 18 in the base case — and at month 10 to 12 in a slip scenario, with significantly worse pricing power. EY 2025 data confirm this is not an edge case: 39% of biotechs are already below 12 months of cash. The modal clinical-stage CFO is navigating toward a forced financing event that the runway model did not flag.

4. What the Financing Data Confirm

The post-2022 market has moved. Investors have priced in the gap — even if internal models have not.

SVB's mid-2023 tracking showed crossover round count falling from 108 in 2021 to 33 in 2022 to 11 by mid-2023. William Blair's Q2 2025 Quarterly Rx found more than 50% of public biotechs ended 2024 with less than two years of runway. Stifel counted 180 public biotechs with market caps below their cash holdings at mid-2023 — a figure comparable to 2008–2009. Jefferies tracked 128 to 150+ small- and mid-cap public biotechs trading below net cash in 2022.

What sophisticated investors now require at a Series B or C close: 24 to 36 months of pro-forma runway to a meaningful clinical inflection point. That figure has been consistent across Stifel, Jefferies, SVB, and William Blair commentary since 2023. The gap between what investors require and what many CFO models produce is not a negotiating position. It is the difference between raising at a step-up and raising at a discount.

The dilution math clarifies the stakes. A planned crossover round at 18 to 12 months before a value-inflection readout historically prices at a 1.6× step-up to IPO (Clough Capital, 2024). A forced convertible bridge in the current market, with standard 50% to 100% warrant coverage and anti-dilution provisions, produces 25% to 40% effective dilution to common — at no step-up. Wilson Sonsini's H1 2025 PIPE and RDO report found life-sciences PIPEs priced at an average 5.2% headline discount, which looks manageable until warrant coverage is applied. The effective cost of financing from weakness is roughly 10 to 25 dilution points higher than financing from strength.

CRO pass-throughs compound the problem further. Medpace's FY2024 10-K shows reimbursed out-of-pocket expenses of $770.7M against total direct costs of $1,452.7M — 53% of direct costs. ICON's Q4 2024 earnings commentary flagged that pass-through mix would increase in H1 2025, noting pass-throughs carry little to no margin impact. Site fees, central lab, IRT, and translational assays are the operational lines exposed to enrollment-driven overruns. A CFO negotiating direct service fees is fighting over the smaller half of the budget.

Implication

The structural pattern is straightforward. Clinical-stage biotechs are being built on timeline assumptions that do not match published trial-duration data, cost assumptions that do not account for the 76% amendment rate and its associated schedule impact, and runway targets that investors abandoned in 2022. The result is a category of company that is systematically arriving at its financing moment too late, in a market where the price of late is measured in dilution points. The CFO who discovers this gap before the auditor or the banker has options. The CFO who discovers it in a going-concern review does not.